BioAtla (BCAB) Competitors $0.41 +0.01 (+2.51%) As of 01:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCAB vs. CLLS, ADAG, ONCY, CLYM, ELUT, ENTX, TCRX, EXOZ, CABA, and JMACShould you be buying BioAtla stock or one of its competitors? The main competitors of BioAtla include Cellectis (CLLS), Adagene (ADAG), Oncolytics Biotech (ONCY), Climb Bio (CLYM), Elutia (ELUT), Entera Bio (ENTX), TScan Therapeutics (TCRX), eXoZymes (EXOZ), Cabaletta Bio (CABA), and Maxpro Capital Acquisition (JMAC). These companies are all part of the "pharmaceutical products" industry. BioAtla vs. Its Competitors Cellectis Adagene Oncolytics Biotech Climb Bio Elutia Entera Bio TScan Therapeutics eXoZymes Cabaletta Bio Maxpro Capital Acquisition BioAtla (NASDAQ:BCAB) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk. Which has more volatility and risk, BCAB or CLLS? BioAtla has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Comparatively, Cellectis has a beta of 2.91, meaning that its share price is 191% more volatile than the S&P 500. Do insiders and institutionals hold more shares of BCAB or CLLS? 77.2% of BioAtla shares are held by institutional investors. Comparatively, 63.9% of Cellectis shares are held by institutional investors. 11.5% of BioAtla shares are held by company insiders. Comparatively, 16.4% of Cellectis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts recommend BCAB or CLLS? BioAtla currently has a consensus target price of $5.00, indicating a potential upside of 1,122.49%. Cellectis has a consensus target price of $4.00, indicating a potential upside of 93.70%. Given BioAtla's higher probable upside, analysts plainly believe BioAtla is more favorable than Cellectis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioAtla 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Cellectis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is BCAB or CLLS more profitable? BioAtla has a net margin of 0.00% compared to Cellectis' net margin of -114.82%. Cellectis' return on equity of -62.55% beat BioAtla's return on equity.Company Net Margins Return on Equity Return on Assets BioAtlaN/A -373.47% -116.55% Cellectis -114.82%-62.55%-21.19% Which has higher valuation and earnings, BCAB or CLLS? Cellectis has higher revenue and earnings than BioAtla. Cellectis is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioAtla$11M2.17-$69.78M-$1.22-0.34Cellectis$49.22M2.33-$36.76M-$0.86-2.40 Does the media prefer BCAB or CLLS? In the previous week, BioAtla and BioAtla both had 1 articles in the media. Cellectis' average media sentiment score of 1.87 beat BioAtla's score of 0.93 indicating that Cellectis is being referred to more favorably in the news media. Company Overall Sentiment BioAtla Positive Cellectis Very Positive SummaryCellectis beats BioAtla on 10 of the 14 factors compared between the two stocks. Get BioAtla News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCAB vs. The Competition Export to ExcelMetricBioAtlaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.89M$2.91B$5.52B$9.33BDividend YieldN/A2.43%4.59%4.02%P/E Ratio-0.3420.4228.6919.67Price / Sales2.17189.51364.2674.65Price / CashN/A41.0524.7327.56Price / Book1.647.658.205.59Net Income-$69.78M-$55.11M$3.24B$257.73M7 Day Performance5.39%8.27%2.50%1.34%1 Month Performance0.86%12.07%8.54%11.13%1 Year Performance-76.63%1.25%28.77%15.90% BioAtla Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCABBioAtla2.0523 of 5 stars$0.41+2.5%$5.00+1,122.5%-77.8%$23.89M$11M-0.3460CLLSCellectis3.3181 of 5 stars$1.60+1.3%$4.00+150.0%+2.9%$87.82M$49.22M-1.86290Positive NewsGap UpADAGAdagene2.6003 of 5 stars$1.95+5.4%$8.00+310.3%-33.0%$87.15M$100K0.00260Gap UpONCYOncolytics Biotech1.5083 of 5 stars$1.01+9.8%$4.33+329.0%+15.4%$86.73MN/A-3.4830High Trading VolumeCLYMClimb Bio3.5187 of 5 stars$1.26-1.6%$9.00+614.3%N/A$86.50MN/A-0.539Gap UpELUTElutia3.7329 of 5 stars$2.08-0.5%$8.00+284.6%-53.4%$85.93M$24.38M-1.08180ENTXEntera Bio2.6018 of 5 stars$1.83-3.2%$10.00+446.4%-5.3%$85.91M$180K-7.0420TCRXTScan Therapeutics3.6006 of 5 stars$1.45-4.0%$7.80+437.9%-71.5%$85.45M$2.82M-1.33100News CoverageAnalyst UpgradeEXOZeXoZymesN/A$10.18+2.7%N/AN/A$82.93M$70K0.0029Positive NewsGap DownCABACabaletta Bio2.799 of 5 stars$1.49-8.6%$14.43+868.4%-79.5%$82.71MN/A-0.5950News CoverageJMACMaxpro Capital AcquisitionN/A$6.14-6.4%N/A+2,686.3%$82.45MN/A0.002,021 Related Companies and Tools Related Companies CLLS Alternatives ADAG Alternatives ONCY Alternatives CLYM Alternatives ELUT Alternatives ENTX Alternatives TCRX Alternatives EXOZ Alternatives CABA Alternatives JMAC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCAB) was last updated on 7/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioAtla, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioAtla With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
